Genmab Retained Earnings (Accumulated Deficit) 2019-2024 | GMAB

Genmab retained earnings (accumulated deficit) for the quarter ending September 30, 2024 were $2.892B, a 7.37% increase year-over-year.

  • Genmab retained earnings (accumulated deficit) for 2023 were $2.762B, a 30.32% increase from 2022.
  • Genmab retained earnings (accumulated deficit) for 2022 were $2.119B, a 32.95% increase from 2021.
  • Genmab retained earnings (accumulated deficit) for 2021 were $1.594B, a 46.42% increase from 2020.

Genmab Retained Earnings (Accumulated Deficit) 2019-2024 | GMAB

  • Genmab retained earnings (accumulated deficit) for 2023 were $2.762B, a 30.32% increase from 2022.
  • Genmab retained earnings (accumulated deficit) for 2022 were $2.119B, a 32.95% increase from 2021.
  • Genmab retained earnings (accumulated deficit) for 2021 were $1.594B, a 46.42% increase from 2020.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$173B
Vertex Pharmaceuticals (VRTX)$129.4B
Gilead Sciences (GILD)$121.9B
Bristol Myers Squibb (BMY)$111B
CSL (CSLLY)$91.9B
Regeneron Pharmaceuticals (REGN)$90.6B
GSK (GSK)$76B
Argenex SE (ARGX)$35.4B
Alnylam Pharmaceuticals (ALNY)$35.1B
BioNTech SE (BNTX)$25.7B
Biogen (BIIB)$25.3B
Illumina (ILMN)$24.6B
BeiGene (BGNE)$20.1B
Moderna (MRNA)$19.3B
Incyte (INCY)$15.9B
Insmed (INSM)$12.8B
Vaxcyte (PCVX)$12.8B
BioMarin Pharmaceutical (BMRN)$12.8B
Bio-Techne Corp (TECH)$12.1B
Sarepta Therapeutics (SRPT)$11.5B
Exelixis (EXEL)$10.2B
QIAGEN (QGEN)$10.1B
Revolution Medicines (RVMD)$9.9B
Exact Sciences (EXAS)$9.9B
Intra-Cellular Therapies (ITCI)$9.6B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$8.7B
Repligen (RGEN)$8.1B
Ascendis Pharma (ASND)$7.7B
Viking Therapeutics (VKTX)$7.7B